Penn sued BioNTech in August alleging the university was owed more in royalty payments for the use of the university's patented technology in a Covid-19 vaccine. BioNTech has agreed to pay the ...

The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the payment of royalties related to its COVID-19 ...

After the University of Pennsylvania and the U.S. National Institutes of Health (NIH) separately pressed BioNTech for royalties on its Pfizer-partnered COVID-19 vaccine Comirnaty, the German ...

Penn has agreed to dismiss with prejudice the litigation Penn filed against the Company and its former subsidiary, BioNTech RNA Pharmaceuticals, in the U.S. District Court for the Eastern District ...

Concurrently, BioNTech (BNTX) announced a settlement agreement worth $467M with Penn to resolve a lawsuit filed by the university over royalty claims related to the COVID-19 shot. The deal ...

The settlements will see BioNTech pay $791.5 million to NIH and $467 million to Penn, with Pfizer (PFE), its vaccine partner, reimbursing part of these payments. The dispute stemmed from claims by ...

BioNTech has agreed to pay $1.26 billion across two separate settlements with the National Institutes of Health and the University of Pennsylvania tied to royalties for its Covid-19 vaccine. The ...